上海先锋控股有限公司

China Pioneer Pharma Holdings Limited ("Pioneer Pharma") was established in 1996. As a comprehensive marketing, promotion and channel management service provider for imported pharmaceutical and medical device products, Pioneer Pharma continuously introduces a series of products representing internationally advanced technology levels to the domestic pharmaceutical market, benefiting numerous patients. On November 5, 2013, Pioneer Pharma was successfully listed on the Main Board of the Hong Kong Stock Exchange (Stock Code: HK.01345).

As an international enterprise with a global vision, Pioneer Pharma has established stable and mutually beneficial long-term cooperative relationships with many globally renowned pharmaceutical and medical device manufacturers, successfully building a product introduction platform for sustainable development, and establishing a sales network covering the entire Chinese market. Long-term efforts have forged Pioneer Pharma's unique brand foundation.

Pioneer Pharma has successively established long-term and stable cooperative relationships with multiple internationally renowned pharmaceutical and medical device manufacturers, including Alcon of the United States, Alfasigma of Italy, Aenova of Germany, Polichem of Switzerland, Fleet of the United States, Ivoclar Vivadent of Liechtenstein (Wieland of Germany), NovaBay of the United States, and others. In Pioneer Pharma's product portfolio, pharmaceuticals cover therapeutic areas such as ophthalmology, anti-inflammatory and analgesic, cardiovascular system, digestive system, immune regulation and gynecology, while medical devices cover multiple therapeutic areas such as ophthalmology, orthopedics, dentistry, and wound care. Pioneer Pharma continuously strives to enhance the market value of these brands.

Relying on a strong sales team, Pioneer Pharma has established a sales system covering all parts of the country, and has established stable cooperative relationships with more than 500 mainstream pharmaceutical distributors across the country. Pioneer Pharma's products have achieved effective coverage in tens of thousands of hospitals, medical institutions and pharmacies nationwide.

In addition, Pioneer Pharma has gradually carried out a globalization strategy, investing in overseas partner companies and innovative R&D companies, and has successively acquired partial equity in the U.S. high-end wound care company NovaBay, the Australian medical device company Paragon, and the Spanish animal vaccine R&D company WorldPathol. Through overseas investment, Pioneer Pharma has further deepened cooperation with overseas companies and gradually moved toward the goal of becoming an international company.

Looking ahead, Pioneer Pharma will leverage its own competitive advantages, including an open development mindset, forward-looking new product introduction capabilities, precise product positioning, a comprehensive marketing network, and an efficient business management system, to adapt to the transformation of the pharmaceutical industry, seize opportunities, deepen market cultivation, and achieve long-term sustainable development.